CD28 and autoimmune disease: sCTLA-4Ig has been shown to modulate the CD28/CD80-CD86 pathway and inhibit T cell activation (39–44); in clinical trials, formulations of CTLA-4Ig have proved to be effective in the treatment of autoimmune diseases and allograft rejection (45–51).